GlaxoSmithKline

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Pharmaceuticals; Pharmaceuticals R&D; Vaccines and Consumer Healthcare. The Pharmaceuticals segment focuses on developing medicines in respiratory and infectious diseases, oncology, and immuno-inflammation. The Pharmaceuticals R&D segment focuses on science related to the immune system, the use of human genetics and advanced technologies, and is driven by the multiplier effect of Science x Technology x Culture. The Vaccines segment produces pediatric and adult vaccines to prevent a range of infectious diseases including, hepatitis A and B, diphtheria, tetanus and whooping cough, measles, mumps and rubella, polio, typhoid, influenza, and bacterial meningitis. The Consumer Healthcare segment develops and markets brands in the oral health, pain relief, respiratory, nutrition and gastro intestinal, and skin health categories. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Vir Biotechnology

The companies are taking multiple approaches to develop treatments and vaccines for the disease caused by the novel coronavirus.

GlaxoSmithKline and Vir Biotechnology Jump in Race to Treat and Prevent COVID-19

U.K. pharmaceutical GlaxoSmithKline GSK, -1.48% GSK, +0.33% said it's making an equity investment in Vir Biotechnology VIR, -0.88% as part of a collaboration to research and develop solutions for coronaviruses.

Vir Biotechnology shares surge on news Glaxo taking $250 million stake

British drugmaker GlaxoSmithKline Plc will invest $250 million in Vir Biotechnology Inc and collaborate to develop potential treatments for COVID-19, the disease caused by the new coronavirus, the companies said on Monday.

GSK to partner with Vir for potential COVID-19 treatments, invest $250 million

Glaxo's (GSK) phase III study on Nucala in patients with chronic rhinosinusitis with nasal polyps (CRSwNP) meets co-primary endpoints.

Glaxo's Nasal Polyps Study on Nucala Meets Primary Endpoints

LONDON and SAN FRANCISCO, April  06, 2020  (GLOBE NEWSWIRE) -- LSE announcement -- GlaxoSmithKline plc (LSE/NYSE: GSK) and Vir Biotechnology, Inc. (Nasdaq: VIR) today announced they have signed a binding agreement to enter into a collaboration to research and develop solutions for coronaviruses, including SARS-CoV-2, the virus that causes COVID-19.

GSK and Vir Biotechnology enter collaboration to find coronavirus solutions

It is the latest in a series of collaborations between the big pharmaceutical company and entities researching potential vaccines for the disease.

GlaxoSmithKline Re-Teams With Chinese Biotech For COVID-19 Vaccine

Should investors buy shares of GlaxoSmithKline before the company completes its ongoing metamorphosis?

Is GlaxoSmithKline Stock a Buy?

Inovio Pharmaceuticals

Johnson & Johnson

Moderna

Sanofi

Vaxart

Just like the flu vaccine, pharmacists should be empowered to administer the COVID-19 vaccine to patients in every state.

Expand Pharmacists’ Authority To Promote COVID-19 Vaccine Access

Apple

Bank of America

Your coronavirus stimulus check could be the perfect excuse to go shopping for bargains in the stock market.

3 Top Stocks to Buy With Your $1,200 Stimulus Check

Walmart

Things could still get worse in the markets, and that's why now may be a good time to load up on these stocks.

3  Stocks to Buy  Ahead of the Next Market Crash

Glaxo's (GSK) long-acting injectable regimen of cabotegravir and rilpivirine gets its first approval for the treatment of HIV-1 infection in virologically-suppressed adults

Glaxo's Long-Acting HIV Regimen Cabenuva Gets Canada's Nod

Last week, analysts parsed 406 filings and collected 39,443 data points. In total, they made 6,642 accounting adjustments with a dollar value of $1.6 trillion.

Restructuring Charges Obscure GlaxoSmithKline’s True Profits

Both of these companies are in the thick of the hunt to develop a coronavirus vaccine. Which stock is the better pick right now?

Better Coronavirus Stock: Inovio Pharmaceuticals or GlaxoSmithKline?

BioNTech SE

Gilead Sciences

Eli Lilly

Pfizer

Takeda Pharmaceutical

The battle to defeat the coronavirus will be won. But victory won't come as quickly as anyone would like.

Big Pharma's Fight Against the Coronavirus Pandemic: Good News and Bad News

A Relative Strength Rating upgrade for Glaxosmithkline shows improving technical performance. Will it continue?

Stocks Showing Improved Relative Strength: Glaxosmithkline

Biogen

While the overall vaccine development process has been impressively fast so far, it might take 12-18 months to fully validate a potential vaccine.

Coronavirus Vaccine Trial Begins, Biotech Competition Heats Up

In the battle between these pharma heavyweights, which one’s prospects shine brightest?

Better Buy: Pfizer vs. GlaxoSmithKline

Cocrystal Pharma

NanoViricides

Novavax

The COVID-19 virus has sent the market and the global economy into a tailspin. The Organisation for Economic Co-operation and Development slashed its global growth forecast for 2020 Monday by 0.5 points to 2.5% versus already-weak 2.9% growth in 2019.

How Close Are Biotechs To Bringing A COVID-19 Treatment To Market?

The drug combination has to be injected, but only having to deal with treatment once a month could be worth it for many patients.

Pfizer, GlaxoSmithKline, Johnson & Johnson Team Up on Once-Monthly HIV Treatment

Regeneron Pharmaceuticals

7 Big Pharma Companies Trump Asked to Fight the Coronavirus Outbreak

February was a wild month as coronavirus fears drove the pharma's stock price up and down.

Why Shares of GlaxoSmithKline Dropped 12.4% in February

Bristol-Myers

Epizyme

On the heels of an FDA approval and with another due soon, investors may want to participate in a biotech that boasts It's

Smart Money Is Clamoring to Own This Cancer-Fighting Biotech

The divestment of its cephalosporin products could bring in several hundred million dollars.

GlaxoSmithKline Reportedly Trying Again to Sell Antibiotics Line

President Donald Trump asks pharmaceutical companies working on making vaccines or treatments for coronavirus to accelerate development.

Trump Asks Pharma Firms to Step Up Coronavirus Vaccine Work

As the coronavirus outbreak continues to spread, some of the biggest drug companies are moving closer to finding a vaccine.

These 6 Drug Companies are Testing a Coronavirus Vaccine

News for GlaxoSmithKline Stock (GSK)